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Abstract
Human arylamine N-acetyltransferase 1 (hNAT1) has become an attractive potential biomarker for estrogen-receptor-
positive breast cancers. We describe here the mechanism of action of a selective non-covalent colorimetric biosensor for the
recognition of hNAT1 and its murine homologue, mNat2, over their respective isoenzymes, leading to new opportunities in
diagnosis. On interaction with the enzyme, the naphthoquinone probe undergoes an instantaneous and striking visible
color change from red to blue. Spectroscopic, chemical, molecular modelling and biochemical studies reported here show
that the color change is mediated by selective recognition between the conjugate base of the sulfonamide group within
the probe and the conjugate acid of the arginine residue within the active site of both hNAT1 and mNat2. This represents a
new mechanism for selective biomarker sensing and may be exploited as a general approach to the specific detection of
biomarkers in disease.
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Introduction
Diagnosis of breast cancer combines non-invasive examinations,
such as mammography, ultrasound or magnetic resonance
imaging and biopsy tests. At the present time, the analysis of
biological samples allows the identification of tumor-specific
biomarkers to stratify anti-target therapies [1–3]. A variety of
chemical approaches have been developed to selectively detect and
monitor biomolecules, and to generate novel molecular sensors for
biological markers to facilitate diagnosis with improved accuracy
[4–7].
Proteomic and microarray analyses have identified the overex-
pression of human arylamine N-acetyltransferase 1 (hNAT1) in estrogen-
receptor-positive ductal and lobular breast cancers [8–10] and
more recently in male breast cancers [11]; furthermore, this
overexpression inversely correlates to tumor grade [12]. In
addition to its catalytic role as an arylamine-metabolizing enzyme
using acetyl coenzyme A (AcCoA) as cofactor [13] subsequent
studies have assessed hNAT1 as a new biomarker to be developed
as a novel diagnostic, prognostic and potential therapeutic target
in breast cancers [10–11].
We have previously described a family of naphthoquinones as
non-covalent competitive selective inhibitors of hNAT1 and its
murine homologue mNat2 over other eukaryotic and prokaryotic
isoforms [14–16]. Remarkably, an instantaneous distinctive color
change from red to blue is observed upon binding of these
naphthoquinone ligands, such as compound 1, to both hNAT1
and mNat2, which share more than 80% identity in amino acid
sequence and are functionally homologous (Figure 1) [16–17].
No such shift in the lmax of naphthoquinone 1 was observed in the
presence of the other human and murine NAT enzymes despite
the high number of identical residues (.70%) (Figure 1), nor with
NATs from prokaryotes [16]. Since hNAT1 is a candidate
biomarker in breast cancer, it was reasoned that understanding the
mechanism of recognition and color change between this family of
naphthoquinone probes and hNAT1 could allow both the
development of these probes for tumor subtype diagnosis and
the application of this technology to other protein families.
The observed color change was proposed to be caused by selective
recognition of the conjugate base of the naphthoquinone mediated
by an appropriate residue within the active site of hNAT1 or mNat2,
since a similar bathochromic shift in the lmax of naphthoquinone 1
was also observed in an alkaline solution [16]. Kinetic studies with
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pure recombinant mNat2 have revealed a competitive mode of
inhibition of 1 towards the arylamine substrate para-amino benzoate
(Ki,app. = 420 nM), which is consistent with previous studies using
another member of this naphthoquinone family (Figure 1 and
Figure S1 in File S1) [16].
We describe a set of spectroscopic, chemical, molecular modeling
and biochemical studies to interrogate the key molecular interac-
tions between hNAT1 or its murine homologue, mNat2, and
naphthoquinone 1 which lead to the observed color change event.
Results and Discussion
Reduction of the naphthoquinone core of 1 has previously been
examined and discounted as a possible mechanism for this color
change [16]. Additionally, it was found that the visible spectrum of
1 when treated with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), a
non-nucleophilic amidine base, is comparable to that of 1 in the
presence of aqueous NaOH (Figure S2 in File S1). This strongly
suggests that the observed color change follows an acid-base
interaction rather than a potential nucleophilic addition mecha-
nism to the electrophilic enone system within 1.
Based on the hypothesis that selective recognition of the
conjugate base of 1 within the hNAT1 or mNat2 active site is
responsible for the observed color change, we aimed to identify
both the acidic proton within 1 and the suitably located basic
residue within the enzyme active site.
An acid-base titration revealed the pKa of 1 to be ,9.2 in 5%
DMSO/95% H2O (Figure S3 in File S1), which is consistent
with the deprotonation of the sulfonamide moiety of 1. Although
the sulfonamide-NH could be identified in the 1H-NMR spectrum
of 1 in 100% DMSO-d6 solution (dH = 9.05 ppm) [16], adding as
little as 5% D2O to the DMSO-d6 solvent promoted rapid proton-
deuteron exchange. Direct observation of the sulfonamide-NH
resonance by 1H-NMR spectroscopy could not be carried out
under aqueous alkaline conditions nor in the presence of a NAT
isoform under the assay conditions required for protein integrity
(5% DMSO-d6/95% D2O).
The corresponding 15N-labelled sulfonamide analogue of 1 was
thus synthesized (compound 2) to monitor the sulfonamide-NH
using 15N-NMR spectroscopy. The 15N-NMR spectrum of 2
under alkaline conditions (95% DMSO-d6/5% aqueous NaOD)
was acquired and compared to the spectrum in 100% DMSO-d6
(Figure 2a). The 15N spectrum of 2 under neutral conditions
displayed a sharp resonance at 104.7 ppm, whilst the spectrum
under alkaline conditions showed a broader resonance at
166.3 ppm. The displacement of the 15N chemical shift is
consistent with the electron density changing around the
sulfonamide-15N in an alkaline environment. It was not however
possible to acquire 15N-NMR spectra in the presence of hNAT1 or
mNat2 under conditions in which the protein would be active (5%
DMSO-d6/95% D2O) as 2 was insufficiently soluble.
Therefore, an alternative approach was adopted, whereby a
close analogue of 1 was synthesized incorporating an N-methyl-N-
sulfonyl moiety to determine the effect of removing the possibility
of sulfonamide deprotonation with minimal disruption to other
structural and chemical properties of the molecule. Treatment of 1
with one equivalent of TMS-diazomethane produced a separable
mixture of the N-methyl substituted species 3 and the O-methyl
substituted species 4, which were isolated in 55% and 35% yields
respectively (see File S1).
Compound 3 was found to be a good inhibitor of hNAT1
(IC50 = 5.8 mM), but a very poor inhibitor of mNat2 (IC50
.150 mM), whilst 4 inhibited both enzymes with reasonable
potency (IC50 = 3.6 mM for hNAT1 and IC50 = 14.6 mM for
mNat2) (Figure 2b). Visible spectra of the N-methylated species
3 show that no color change occurs either in aqueous NaOH
solution or in the presence of hNAT1 or mNat2. Visible spectra of
the O-methylated species 4 also do not show an instantaneous shift
in lmax in the presence of mNat2 (Figure 2b and Figures S4
and S5 in File S1). Neither 3 nor 4 was active against the other
Figure 1. Competitive inhibition of 1 towards mNat2 and active site differences in mammalian NATs. (a) Left panel: Structure of
compound 1; Right panel: Dixon plot shows competitive inhibition of mNat2 (9 ng) by 1 at different pABA concentrations (25 mM (circles), 50 mM
(triangles), 100 mM (diamonds), and 250 mM (squares)). Initial rates of the mNat2 catalysed reaction were determined by monitoring the rate of
hydrolysis of AcCoA (400 mM) (b) Summary table of active site differences of human and murine NATs and the effects of their interaction with 1. Blue
and red columns indicate the color of 1 on interaction with the protein.
doi:10.1371/journal.pone.0070600.g001
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human NAT isoenzyme, hNAT2, as more than 90% of enzyme
activity was retained at an inhibitor concentration of 30 mM.
Sulfonate ester 5 was also synthesized, since this compound was
predicted to have similar steric and electronic properties to 1 but
lacks an acidic sulfonamide-NH. As predicted, 5 does not undergo
a color change in the presence of either aqueous NaOH or in the
presence of either hNAT1 or mNat2 (Figure 2b and Figure S6
in File S1). Compound 5 was observed to be a weak inhibitor of
hNAT1 (IC50 = 93 mM) and a very poor inhibitor of mNat2 (IC50
.150 mM).
With structure-activity-relationship data in hand supporting the
key role of sulfonamide deprotonation in the color change event,
structural-based site-directed mutagenesis studies were next
undertaken to establish which amino acid residue within the
active site of hNAT1 or mNat2 is able to recognize the conjugate
base of the sulfonamide moiety within 1.
X-Ray crystal structures of both human NAT enzymes are
available [18]; hNAT1 (PDB:2PQT) was used to build a structural
model for mNat2. 1 was computationally docked within the active
site of hNAT1 (Figure 3a) and into the mNat2 structural model
(Figure 3b). The results from both docking studies were
compared and several distinctive interactions between 1 and
hNAT1 or mNat2 were predicted.
The close proximity of the sulfonamide functionality of the
ligand and the Arg127 guanidine of both enzymes in the docking
models suggested this residue was important for mutual recogni-
tion. In particular, both a sulfonamide oxygen atom and the
carbonyl group at C1 of the naphthoquinone core of 1 appear to
be able to form a hydrogen bond with the Arg127 guanidine group
in the range of 2.5–3.0 A˚. Meanwhile, the other sulfonamide
oxygen appears close in space to the backbone amide carbonyl of
Phe287 (2.5 A˚).
Further notable potential interactions include the hydrophobic
van der Waals interactions between the naphthoquinone core of 1
and the hydrophobic plane defined by the side chain arene of
Phe125 and the isopropyl side chain of Val93 (3.5–4.0 A˚); and
additionally, the parallel-displaced p-p stacking between the C2
sulfonamide arene of 1 and the side chain arene of Tyr129 (4.2–
4.8 A˚).
The unique presence of the triad Phe125, Arg127 and Tyr129
in both hNAT1 and mNat2 compared to other eukaryotic and
prokaryotic isoenzymes strongly supports the key role of these
residues in selective ligand binding. This observation is consistent
with previous findings on the crucial role played by the same
residues on arylamine substrate preference [18–20]. Arg127 is not
found in any of the other NAT enzymes investigated here
(Figure S7 in File S1).
It was important to rule out the involvement of the catalytic
Cys68 residue in mediating the color change event. Selective
alkylation of the Cys68 thiolate within the mNat2 active site by
incubating mNat2 with iodoacetamide inactivates the enzyme, but
does not prevent the ligand 1 from changing color in the presence
of the modified enzyme. This provides evidence to suggest that
Figure 2. Requirement for the acidic proton of sulfonamide-NH for the color change event. (a) Upper: 15N-NMR spectrum of 2 in 95%
DMSO-d6/5% H2O. Image of 50 mL of 2 (2 mM) in DMSO with 10 mL of 20 mM Tris.HCl, pH 8. Lower:
15N-NMR spectrum of 2 in 95% DMSO-d6/5% aq.
NaOD (final NaOD concentration 75.8 mM). Image of 50 mL of 2 (2 mM) in DMSO with 10 mL of 4 mM NaOH, pH 13. (b) Comparison of the
colorimetric and inhibitory properties of compounds 1, 3, 4 and 5 towards hNAT1 and mNat2. Colors of cells indicate the observed color of the
relevant compound under the given conditions.
doi:10.1371/journal.pone.0070600.g002
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Cys68 is not the residue responsible for the color change
(Figures S8 and S9 in File S1).
Arg127, which is likely to be protonated under the assay
conditions (pH 8), is therefore anticipated to interact with the
conjugate base of the sulfonamide moiety on binding of ligand 1,
thereby driving the observed color change of 1 from red to blue,
as the conjugate base of 1 is sequestered by the enzyme. From a
chemical perspective, this accords with the pKaH of a free
arginine guanidine (,12.5) being higher than the pKa of 1
(,9.2). The proposed mode of recognition between the protein
and the ligand generates a strong bidentate ionic interaction
between the two counterparts, an important feature contributing
to selective recognition and stability of the protein/ligand
complex.
Arg127 in mNat2 was therefore mutated by site-directed
mutagenesis. Two different mutant mNat2 constructs were
generated after single nucleotide mutation: the first encoding for
a Gly at position 127 (mNat2_R127G), and the second for a Leu
(mNat2_R127L, Figure S10 in File S1). By substituting Leu in
place of Arg, a basic, charged group is removed with only a minor
reduction in the predicted active site volume. Substitution for Gly
significantly alters the overall size and shape of the active site.
Moreover, Gly is the residue present at the same position in the
other murine isoenzyme, mNat1. Wild type mNat2 (mNat2_WT)
and the two mutants were successfully produced as recombinant
proteins and purified with good yields ($40 mg/L culture)
consistent with previous studies on mNat2_WT (Figures S11
and S12 and Table S1 in File S1) [17].
Both site-directed mutants were found to be catalytically active:
whilst the R127G mutant has a similar specific activity to the
native protein with pABA as substrate (920 nmol/min/mg
compared to 850 nmol/min/mg for mNat2_WT), the R127L
mutant is less active (13 nmol/min/mg). Each of the mutants are
also active against anisidine and showed no activity towards
procainamide, like mNat2_WT, suggesting the proteins are
appropriately folded to be catalytically active. AcCoA-hydrolysis
assays were therefore carried out to investigate their kinetic
properties towards naphthoquinone 1. The activity of each mNat2
mutant enzyme was tested with different concentrations of the
inhibitor and IC50 curves were obtained and compared (Figure 4).
The IC50 value of 1 with mNat2_WT was 1.9 mM, whereas the
IC50 values with mNat2_R127G and mNat2_R127L were higher,
at 51.7 and 102.5 mM respectively.
Full visible wavelength scans were obtained with 1 in the
presence of the three mNat2 variants at pH 8.0. A bathochromic
shift was observed with mNat2_WT, but no color change was
observed with either mNat2_R127G or mNat2_R127L
(Figure 4). This supports the hypothesis that Arg127 is key in
binding of the ligand to the enzyme and is required for the
concomitant color change.
Conclusions
In summary, the combination of inhibitor structural studies,
docking results and mutagenesis studies conducted indicate the
color change observed is driven by selective recognition between
the conjugate base of the sulfonamide-NH of the ligand and the
Arg127 guanidininum of the enzyme. The high selectivity and
striking colorimetric properties of the naphthoquinone probe 1
towards hNAT1 strongly support the further development of this
family of naphthoquinones as selective inhibitors and colorimet-
ric biosensors to target native overexpressed hNAT1 in breast
tumors.
Materials and Methods
Chemicals and reagents
All chemicals were purchased from Sigma-Aldrich UK, TCI
UK, Apollo Scientific UK, Alfa Aesar UK, Fluorochem UK or
Fisher Scientific UK unless otherwise stated. Molecular biology
reagents were obtained from Promega (Southampton, UK).
Competent E. coli cells were purchased from Promega and
Invitrogen (Carlsbad, USA). The pH of buffer solutions was
adjusted at the appropriate temperature.
Chemical synthesis
The description of the methods for the chemical synthesis of
compounds and their characterization data are detailed in the
File S1.
Figure 3. Inhibitor binding pocket of hNAT1 and mNat2. (a) The active site of hNAT1 crystal structure (PDB:2PQT) in surface representation
with 1 docked in stick representation. The hNAT1 residues involved in inhibitor binding and selectivity are shown in stick representation and labeled
with carbon in green, nitrogen in blue, oxygen in red, and sulfur in yellow. 1 is labeled with carbon atoms in light orange, nitrogen in blue, oxygen in
red, and sulfur in yellow. (b) The active site of mNat2 structural model with docked compound 1 is shown using the same representation as in (a).
doi:10.1371/journal.pone.0070600.g003
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Site-directed mutagenesis and transformation
The pET28b(+) plasmid vector containing the sequence of
mNat2 [17] was isolated from 5 mL overnight bacterial cultures
using a QIAprep spin miniprep kit (Qiagen). Site-directed
mutagenesis was achieved using QuikChange II kit (Stratagene)
to mutate one of the three nucleotides (CGT) encoding for Arg127
in mNat2. The reaction mixture (50 mL), which contained 5 mL
106 reaction buffer, 50 ng pET28b(+) plasmid as template,
125 ng of both R127G forward (59-
GCTGGGTTTGGAGGTTCCTACCAGATGTGGGAGCC-
39) and R127G reverse (59-GGCTCCCACATCTGGTAG-
GAACCTCCAAACCCAGC-39) primers, or 125 ng of both
R127L forward (59-GCTGGGTTTGGACTTTCCTACCA-
GATGTGGGAGCC-39) and R127L reverse (59-GGCTCCCA-
CATCTGGTAGGAAAGTCCAAACCCAGC-39) primers, and
1 mL dNTP mix, was subjected to thermo-cycling: one cycle of
2 min. at 95uC, 30 cycles of 1 min. at 95uC, 30 s at 60uC, and
1 min. at 72uC, an extra cycle at 72uC for 10 min., and a final
cycle at 4uC for 5 min. The un-mutated parental DNA template
present in the PCR product was digested by 10 U of Dpn I (New
England Biolabs) for 1 h at 37uC. Mutant plasmids were verified
by sequencing analysis (GeneService at Department of Biochem-
istry, University of Oxford, UK) to ensure the correct change
before transformation by the heat shock method [21] into E. coli
JM109 and E.coli Rosetta(DE3)pLysS strains, as previously
described [17].
Protein production, purification and characterization
All recombinant mouse enzymes including the site-directed
mutants of mNat2 were expressed with a hexa-histidine tag from
E.coli Rosetta(DE3)pLysS strain transformed with the appropriate
plasmid and the protein was then purified via Ni-NTA affinity
chromatography (Qiagen) and thrombin cleavage of the His-tag,
as previously described [17]. Details of the purification steps are
shown in SDS page gels and in purification tables reported in the
(Figures S11 and S12 and Table S1 in File S1). Pure
recombinant hNAT1 was produced as previously described [22].
Enzymatic assays
NAT activity was determined as previously described [15],[23];
a full procedure is outlined in the (File S1).
Colorimetric properties of inhibitors
Visible spectra of each compound were recorded with a U-2001
spectrophotometer (Hitachi) using 1 mL plastic cells of 1 cm path-
length (FisherBrand) or 50 mL UVettesH (Eppendorf). Concentra-
tions of inhibitors and protein used are given in the appropriate
figure legends. All spectra were blank-corrected.
Covalent modification of pure recombinant mNat2
To an aliquot of mNat2 (100 mL at 4 mg/mL in 20 mM
Tris.HCl, pH 8) was added 5 mL 2-iodoacetamide (0.105 M
solution in DMSO) to a final concentration of 5 mM 2-
iodoacetamide. The aliquot was incubated at 4uC for 3 h, as
previously described [18],[24–25]. Enzymatic activity was abol-
ished and MS (MALDI) support covalent modification of Cys68
within mNat2, consistent with previous studies (Figures S8 and
S9 in File S1, m/z 33988 (unmodified enzyme); 34046 (modified
enzyme)) [18],[24–25].
Modelling structures
All images showing protein structures were generated using the
software PyMOL (W. L. DeLano (2002) PyMOL, DeLano
Scientific, San Carlos, CA). A structural model of mNat2 was
generated based on the hNAT1 structure (PDB:2PQT) using the
on-line software SwissModel, Automated mode (http://
Figure 4. The effects of mutating Arg127 of mNat2 in the interaction with 1. (a) Visible spectra of compound 1 (15 mM) incubated under
different conditions: 20 mM Tris.HCl at pH 8.0 (red line), with mNat2 variants (30 mM) in 20 mM Tris.HCl at pH 8.0 (mNat2_WT (light blue line),
mNat2_R127G (orange line), mNat2_R127L (green line)) or of compound 1 in 80 mM NaOH at pH 13.75 (dark blue line). (b) Summary of interactions
of 1 with hNAT1, mNat2 and the two engineered mNat2 mutants.
doi:10.1371/journal.pone.0070600.g004
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swissmodel.expasy.org/) [26–28], after removing the acetanilide
molecule and restoring the thiol functionality of Cys68. The
docking studies on 1 within hNAT1 and mNat2 active sites were
conducted as follows. The ligand was first drawn as a 3D structure
using the software ChemBio3D Ultra 12.0. The molecular editor
Avogadro was used to predict the ground state conformation of the
ligand. The analysis of the possible interactions between the
protein and the ligand was performed using the licensed software
GOLD [29]. A docking site was defined as a region of 10 A˚ within
the active pocket of the enzyme and the ligand was then loaded
into the software. The software gave different docked conformers
and ranked the generated solutions using the GOLD Score Fitness
function [29].
Supporting Information
File S1 Synthetic procedures, analytical data, NMR
spectra and HPLC traces for all reported compounds,
supplementary figures and tables (Figures S1–S12; Ta-
ble S1) can all be found in File S1.
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